Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01273766 · ClinicalTrials.gov registry record · Phase 2
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT01273766: Completed Phase 2 study, sponsored by Wake Forest University Health Sciences.
NCT01273766 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01273766, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
RATIONALE: Deferasirox may remove excess iron from the body caused by blood transfusions. PURPOSE: This clinical trial studies deferasirox in treating iron overload caused by blood transfusions in patients with hematologic malignancies.
Primary Outcome
Changes in Neutrophils between baseline and mean neutrophils values during treatment (measured after each dose)
Interventions
- OTHER laboratory biomarker analysis
- OTHER enzyme-linked immunosorbent assay
- DRUG deferasirox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2011-01 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
What the finished NCT01273766 record still lists
NCT01273766 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01273766 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01273766 about?
NCT01273766 is a clinical study titled "Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies". RATIONALE: Deferasirox may remove excess iron from the body caused by blood transfusions. PURPOSE: This clinical trial studies deferasirox in treating iron overload caused by blood transfusions in patients with hematologic malignancies.
What is the current status of trial NCT01273766?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2011-01. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01273766?
The interventions under investigation include: laboratory biomarker analysis (OTHER), enzyme-linked immunosorbent assay (OTHER), deferasirox (DRUG).
Who is sponsoring clinical trial NCT01273766?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01273766's enrollment target sits among peer trials
16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia